{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:42:31Z","timestamp":1779928951915,"version":"3.53.1"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"7","funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["RO1-CA176078"],"award-info":[{"award-number":["RO1-CA176078"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The initial molecular events that lead to malignant transformation of the fimbria of the fallopian tube (FT) through high-grade serous ovarian carcinoma (HGSC) remain poorly understood. In this study, we report that increased expression of signal transducer and activator of transcription 3 (pSTAT3 Tyr705) and suppression or loss of protein inhibitor of activated STAT3 (PIAS3) in FT likely drive HGSC. We evaluated human tissues-benign normal FT, tubal-peritoneal junction (TPJ), p53 signature FT tissue, tubal intraepithelial lesion in transition (TILT), serous tubal intraepithelial carcinoma (STIC) without ovarian cancer, and HGSC for expression of STAT3\/PIAS3 (compared with their known TP53 signature) and their target proliferation genes. We observed constitutive activation of STAT3 and low levels or loss of PIAS3 in the TPJ, p53 signature, TILT, and STIC through advanced stage IV (HGSC) tissues. Elevated expression of pSTAT3 Tyr705 and decreased levels of PIAS3 appeared as early as TPJ and the trend continued until very advanced stage HGSC (compared with high PIAS3 and low pSTAT3 expression in normal benign FT). Exogenous expression of STAT3 in FT cells mediated translocation of pSTAT3 and c-Myc into the nucleus. In vivo experiments demonstrated that overexpression of STAT3 in FT secretory epithelial cells promoted tumor progression and metastasis, mimicking the clinical disease observed in patients with HGSC. Thus, we conclude that the STAT3 pathway plays a role in the development and progression of HGSC from its earliest premalignant states.<\/jats:p>\n                  <jats:p>Significance: Concomitant gain of pSTAT3 Tyr705 and loss of PIAS3 appear critical for initiation and development of high-grade serous carcinoma. Cancer Res; 78(7); 1739\u201350. \u00a92018 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-17-1671","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T09:20:14Z","timestamp":1516094414000},"page":"1739-1750","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["<i>STAT3\/PIAS3<\/i>\n                    Levels Serve as \u201cEarly Signature\u201d Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube"],"prefix":"10.1158","volume":"78","author":[{"given":"Uksha","family":"Saini","sequence":"first","affiliation":[{"name":"1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian A.","family":"Suarez","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Gynecological Pathology and Cytopathology Unit, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Naidu","sequence":"additional","affiliation":[{"name":"1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Wallbillich","sequence":"additional","affiliation":[{"name":"3Division of Gynecologic Oncology, Department of OB\/GYN, Georgia Cancer Center, Augusta University, Augusta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bixel","sequence":"additional","affiliation":[{"name":"1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Wanner","sequence":"additional","affiliation":[{"name":"1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bice","sequence":"additional","affiliation":[{"name":"4Pathology Core Lab, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raleigh D.","family":"Kladney","sequence":"additional","affiliation":[{"name":"4Pathology Core Lab, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Lester","sequence":"additional","affiliation":[{"name":"5Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[{"name":"5Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Goodfellow","sequence":"additional","affiliation":[{"name":"1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[{"name":"1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuppaiyah","family":"Selvendiran","sequence":"additional","affiliation":[{"name":"1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2022061706342435000_bib1","doi-asserted-by":"crossref","first-page":"11620","DOI":"10.1038\/ncomms11620","article-title":"Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution","volume":"7","author":"Bartlett","year":"2016","journal-title":"Nat Commun"},{"key":"2022061706342435000_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061706342435000_bib3","article-title":"SEER stat fact sheets: ovary cancer","year":"2015"},{"key":"2022061706342435000_bib4","doi-asserted-by":"crossref","first-page":"709049","DOI":"10.1155\/2012\/709049","article-title":"Early detection biomarkers for ovarian cancer","volume":"2012","author":"Sarojini","year":"2012","journal-title":"J Oncol"},{"key":"2022061706342435000_bib5","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.1017300108","article-title":"Modeling high-grade serous ovarian carcinogenesis from the fallopian tube","volume":"108","author":"Karst","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706342435000_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"2022061706342435000_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discov"},{"key":"2022061706342435000_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/his.12046","article-title":"Fallopian tube precursors of ovarian low- and high-grade serous neoplasms","volume":"62","author":"Vang","year":"2013","journal-title":"Histopathology"},{"key":"2022061706342435000_bib9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706342435000_bib10","doi-asserted-by":"crossref","first-page":"934261","DOI":"10.1155\/2014\/934261","article-title":"Recent concepts of ovarian carcinogenesis: type I and type II","volume":"2014","author":"Koshiyama","year":"2014","journal-title":"BioMed Res Int"},{"key":"2022061706342435000_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J Pathol"},{"key":"2022061706342435000_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fonc.2013.00217","article-title":"Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms","volume":"3","author":"Jones","year":"2013","journal-title":"Front Oncol"},{"key":"2022061706342435000_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706342435000_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/0008-5472.CAN-15-1382","article-title":"It's totally tubular\u2026.riding the new wave of ovarian cancer research","volume":"76","author":"Perets","year":"2016","journal-title":"Cancer Res"},{"key":"2022061706342435000_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/path.2927","article-title":"Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers","volume":"225","author":"George","year":"2011","journal-title":"J Pathol"},{"key":"2022061706342435000_bib16","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/ijc.29528","article-title":"Mutant p53 expression in fallopian tube epithelium drives cell migration","volume":"137","author":"Quartuccio","year":"2015","journal-title":"Int J Cancer"},{"key":"2022061706342435000_bib17","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1073\/pnas.1117135109","article-title":"High-grade serous ovarian cancer arises from fallopian tube in a mouse model","volume":"109","author":"Kim","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706342435000_bib18","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1038\/onc.2013.394","article-title":"FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis","volume":"33","author":"Levanon","year":"2014","journal-title":"Oncogene"},{"key":"2022061706342435000_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","article-title":"Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers","volume":"74","author":"Karst","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706342435000_bib20","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/cncr.22293","article-title":"The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis","volume":"107","author":"Rosen","year":"2006","journal-title":"Cancer"},{"key":"2022061706342435000_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/onc.2016.197","article-title":"Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target","volume":"36","author":"Saini","year":"2017","journal-title":"Oncogene"},{"key":"2022061706342435000_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2022061706342435000_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1593\/neo.06409","article-title":"Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K\/Akt inactivation","volume":"8","author":"Ogata","year":"2006","journal-title":"Neoplasia"},{"key":"2022061706342435000_bib24","doi-asserted-by":"crossref","first-page":"23216","DOI":"10.1074\/jbc.M111.335927","article-title":"Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein","volume":"287","author":"Sundvall","year":"2012","journal-title":"J Biol Chem"},{"key":"2022061706342435000_bib25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI0215617","article-title":"Stat proteins and oncogenesis","volume":"109","author":"Bromberg","year":"2002","journal-title":"J Clin Invest"},{"key":"2022061706342435000_bib26","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-14-1233","article-title":"Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival","volume":"20","author":"Dabir","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706342435000_bib27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/nprot.2012.097","article-title":"Primary culture and immortalization of human fallopian tube secretory epithelial cells","volume":"7","author":"Karst","year":"2012","journal-title":"Nat Protoc"},{"key":"2022061706342435000_bib28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/onc.2009.402","article-title":"Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis","volume":"29","author":"Levanon","year":"2010","journal-title":"Oncogene"},{"key":"2022061706342435000_bib29","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1158\/0008-5472.CAN-05-4062","article-title":"Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids","volume":"66","author":"Selvendiran","year":"2006","journal-title":"Cancer Res"},{"key":"2022061706342435000_bib30","doi-asserted-by":"crossref","first-page":"28609","DOI":"10.1074\/jbc.M703796200","article-title":"EF24 induces G2\/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression","volume":"282","author":"Selvendiran","year":"2007","journal-title":"J Biol Chem"},{"key":"2022061706342435000_bib31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/1541-7786.MCR-10-0201","article-title":"HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase","volume":"8","author":"Selvendiran","year":"2010","journal-title":"Mol Cancer Res"},{"key":"2022061706342435000_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s13224-013-0419-x","article-title":"Origin of ovarian cancer: molecular profiling","volume":"63","author":"Dutta","year":"2013","journal-title":"J Obstet Gynaecol India"},{"key":"2022061706342435000_bib33","doi-asserted-by":"crossref","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann Oncol"},{"key":"2022061706342435000_bib34","doi-asserted-by":"crossref","first-page":"12645","DOI":"10.1038\/ncomms12645","article-title":"Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status","volume":"7","author":"Coscia","year":"2016","journal-title":"Nat Commun"},{"key":"2022061706342435000_bib35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.18632\/oncoscience.26","article-title":"Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor","volume":"1","author":"McCann","year":"2014","journal-title":"Oncoscience"},{"key":"2022061706342435000_bib36","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/0008-5472.CAN-13-2433","article-title":"HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer","volume":"74","author":"Rath","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706342435000_bib37","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1158\/1078-0432.CCR-08-0618","article-title":"Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression","volume":"14","author":"Brantley","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061706342435000_bib38","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1541-7786.MCR-09-0313","article-title":"The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent","volume":"7","author":"Dabir","year":"2009","journal-title":"Mol Cancer Res"},{"key":"2022061706342435000_bib39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/modpathol.2010.60","article-title":"Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase","volume":"23","author":"Sehdev","year":"2010","journal-title":"Mod Pathol"},{"key":"2022061706342435000_bib40","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.celrep.2016.04.034","article-title":"Direct upregulation of STAT3 by MicroRNA-551b-3p deregulates growth and metastasis of ovarian cancer","volume":"15","author":"Chaluvally-Raghavan","year":"2016","journal-title":"Cell Rep"},{"key":"2022061706342435000_bib41","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/0008-5472.CAN-16-1115","article-title":"The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res"},{"key":"2022061706342435000_bib42","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ejca.2014.05.001","article-title":"BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients\u2013a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)","volume":"50","author":"Ruscito","year":"2014","journal-title":"Eur J Cancer"},{"key":"2022061706342435000_bib43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2015.09.087","article-title":"PIAS3, SHP2 and SOCS3 expression patterns in cervical cancers: relevance with activation and resveratrol-caused inactivation of STAT3 signaling","volume":"139","author":"Zhang","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2022061706342435000_bib44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3892\/mmr.2016.6079","article-title":"Correlative analyses of the expression levels of PIAS3, p-SHP2, SOCS1 and SOCS3 with STAT3 activation in human astrocytomas","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"key":"2022061706342435000_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.molonc.2011.03.004","article-title":"Protein inhibitor of activated STAT3 expression in lung cancer","volume":"5","author":"Kluge","year":"2011","journal-title":"Mol Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/7\/1739\/2777102\/1739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/7\/1739\/2777102\/1739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:46:18Z","timestamp":1655480778000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/7\/1739\/633154\/STAT3-PIAS3-Levels-Serve-as-Early-Signature-Genes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-17-1671","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22417608.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6509886.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22417608","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22417605.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22417605","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6509886","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}